Search

Zentalis Pharmaceuticals Inc

Geschlossen

4.08 8.22

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

3.68

Max

3.87

Schlüsselkennzahlen

By Trading Economics

Einkommen

-42M

-78M

EPS

-0.59

Angestellte

106

EBITDA

-42M

-77M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+134.22% upside

Dividenden

By Acuity

Nächstes Ergebnis

6. Nov. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

25M

356M

Vorheriger Eröffnungskurs

-4.14

Vorheriger Schlusskurs

4.08

Zentalis Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

2. Sept. 2026, 23:56 UTC

Fidelity National Financial shares are higher in after-market trading, recovering from earlier losses but remain below the 20-day moving average.

2. Sept. 2026, 23:56 UTC

MGM Resorts International shares are higher in after-market trading, supported by a broader market response to weaker ADP private payrolls data.

2. Sept. 2026, 23:56 UTC

News

Entergy Corp settled its 2025 forward sale agreements, delivering over 11 million shares for $913 million. Shares are higher in after-market trading.

2. Sept. 2026, 23:56 UTC

Correlated Moves

Equinix Inc. shares are higher in after-market trading, supported by a weaker ADP payrolls report indicating lower job growth than expected.

2. Sept. 2026, 23:56 UTC

Biogen Inc shares are higher in after-market trading, despite no specific news. Broader market dynamics may be influenced by weaker ADP payrolls data.

2. Sept. 2026, 23:56 UTC

Exelixis Inc shares are higher in after-market trading, though no specific news was identified. The broader market reacted to weaker ADP payroll data.

2. Sept. 2026, 23:56 UTC

APA Corp. shares are trading roughly flat in after-market hours. Market sentiment is influenced by weaker ADP payroll data, easing rate hike concerns.

2. Sept. 2026, 23:56 UTC

Abbott Laboratories shares are lower in after-market hours, reflecting a decline since Wednesday's close amid weaker-than-expected job growth reported by ADP.

2. Sept. 2026, 23:56 UTC

Union Pacific Corp shares are lower in after-market hours amid volatility, following disappointing ADP payroll data that may affect Federal Reserve interest rate expectations.

2. Sept. 2026, 23:56 UTC

T Rowe Price Group Inc shares are trading lower in after-market hours following a volatile session amid reactions to weaker-than-expected ADP payroll data.

2. Sept. 2026, 23:52 UTC

Mexico's inflation rate expected to stabilize around 3% amid cautious market sentiment and external risks ahead of September release.

2. Sept. 2026, 23:52 UTC

Mexican Inflation Data Release on September 9, Amid Cautious Optimism and Ongoing Economic Risks.

2. Sept. 2026, 23:52 UTC

Australia's Westpac Consumer Confidence Index set for release on September 8, 2026, amid mixed sentiments and rising economic pressures.

2. Sept. 2026, 23:52 UTC

US ISM Services PMI Expected to Rise Slightly to 54.3, Indicating Continued Expansion Amid Economic Challenges

2. Sept. 2026, 23:52 UTC

Australia's Westpac Consumer Confidence Index set for release amid cautious optimism and external inflation risks on September 8, 2026.

2. Sept. 2026, 23:51 UTC

Dorian LPG Ltd shares are lower in after-market hours, following five consecutive sessions of gains. The decline coincides with a weaker ADP payrolls report.

2. Sept. 2026, 23:51 UTC

Hackett Group Inc shares are lower in after-market hours, continuing a decline since Wednesday's close and trading below their 20-day moving average.

2. Sept. 2026, 23:51 UTC

Champion Homes Inc is rising in after-market trading, supported by gains in the Homebuilding sub-sector. The asset has recovered from earlier session lows.

2. Sept. 2026, 23:51 UTC

Essential Properties Realty Trust shares are higher in after-market trading. Broader market trends and recent economic data may be influencing this movement.

2. Sept. 2026, 23:51 UTC

ETF Constituents
Macro News

State Street Financial Select Sector SPDR ETF rises in after-market hours as weaker job growth eases Fed rate hike concerns and key holdings perform well.

2. Sept. 2026, 23:51 UTC

IQVIA Holdings Inc shares rose in after-market trading, continuing upward momentum amid a broader macroeconomic backdrop following the ADP payrolls report.

2. Sept. 2026, 23:51 UTC

Correlated Moves

Republic Bancorp Inc shares declined in after-hours trading, reflecting broader financial sector weakness amid disappointing job creation data from the ADP report.

2. Sept. 2026, 23:51 UTC

South Plains Financial Inc is trading lower in after-market hours, continuing a trend seen during the regular session amid broader market weakness following a disappointing ADP report.

2. Sept. 2026, 23:51 UTC

Keysight Technologies Inc shares are lower in after-market hours, continuing a decline from earlier in the session amid a challenging trading environment.

2. Sept. 2026, 23:51 UTC

Sylvamo Corp shares are lower in after-market trading, continuing a decline from earlier in the session amid broader market weakness following the ADP payrolls report.

2. Sept. 2026, 23:51 UTC

Maximus Inc shares are higher in after-market trading, rebounding from earlier lows. Weaker ADP payroll data may ease concerns over aggressive Fed rate hikes.

2. Sept. 2026, 23:51 UTC

New York Times Co shares are higher in after-market trading, supported by a solid market backdrop and recent ADP payrolls report indicating slower job growth.

2. Sept. 2026, 23:51 UTC

Best Buy Co Inc shares are higher in after-market trading, supported by gains in the Computer & Electronics Retail sub-sector and maintaining a notable high.

2. Sept. 2026, 23:51 UTC

U.S. equity indices rebound amid weak job growth and rising oil prices, while geopolitical tensions and climbing bond yields raise inflation concerns.

2. Sept. 2026, 23:51 UTC

Asian equity markets decline amid U.S.-Iran tensions and rising bond yields, while U.S. stocks rebound ahead of key jobs data impacting Fed rate outlook.

Peer-Vergleich

Kursveränderung

Zentalis Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

134.22% Vorteil

12-Monats-Prognose

Durchschnitt 8.83 USD  134.22%

Hoch 11 USD

Tief 5 USD

Basierend auf 6 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Zentalis Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

6 ratings

5

Buy

1

Halten

0

Sell

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.
help-icon Live chat